Toward a Disease-Modifying Therapy of Alpha-Synucleinopathies: New Molecules and New Approaches Came into the Limelight
The accumulation of the various products of alpha-synuclein aggregation has been associated with the etiology and pathogenesis of several neurodegenerative conditions, including both familial and sporadic forms of Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). It is now well establish...
Saved in:
| Main Authors: | Mae Upcott, Kirill D. Chaprov, Vladimir L. Buchman |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-12-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/26/23/7351 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lactoferrin as a Candidate Multifunctional Therapeutic in Synucleinopathies
by: Caroline A. Barros, et al.
Published: (2025-04-01) -
A Narrative Review on Biochemical Markers and Emerging Treatments in Prodromal Synucleinopathies
by: Jamir Pitton Rissardo, et al.
Published: (2025-03-01) -
Interactions of alpha-synuclein with membranes in Parkinson's disease: Mechanisms and therapeutic strategies
by: Baoyi Li, et al.
Published: (2024-10-01) -
Alpha-Synuclein Dysregulation in Systemic Pathophysiology of Synucleinopathies
by: Hallie H. Dolin, et al.
Published: (2025-07-01) -
Alpha-synuclein inclusions reduced by PIKfyve inhibition in Parkinson disease cell models
by: Sara Lucas-Del-Pozo, et al.
Published: (2025-10-01)